People with asthma and obesity have a higher risk of death and hospitalization

Published Date: 06 Mar 2023

USA: Asthmatics affected by obesity have a higher risk of asthma attacks and longer hospital stays than non-obese asthmatics...

Read Full News

Latest News

Achieving Clinical Remission in Asthma Care, With Linda Rogers, MD Linda Rogers, MD

Roger discusses how new therapies are transforming asthma treatment, enabling potential clinical remission.

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Lungcast: Resilience and Sustainability: Preparing Healthcare for the Future with Elizabeth Cerceo, MD Albert Rizzo, MD, Elizabeth Cerceo, MD

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Todays Updates

Nalbuphine Extended-Release Reduces Chronic Cough in IPF, with Philip Molyneaux, MBBS Philip Molyneaux, MBBS

New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease Marco Meglio

A phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.

MRI Analysis Shows Stem Cell Therapy Laromestrocel Reduced Neuroinflammation in Mild Alzheimer Disease Isabella Ciccone, MPH

In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.

Phase 3 Trial to Uncover Therapeutic Potential of 5-HT6 Antagonist Masupirdine to Treat Alzheimer Agitation Louie Pasculli

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

Todays Updates

Nalbuphine Extended-Release Reduces Chronic Cough in IPF, with Philip Molyneaux, MBBS Philip Molyneaux, MBBS

New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease Marco Meglio

A phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.

MRI Analysis Shows Stem Cell Therapy Laromestrocel Reduced Neuroinflammation in Mild Alzheimer Disease Isabella Ciccone, MPH

In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.

Phase 3 Trial to Uncover Therapeutic Potential of 5-HT6 Antagonist Masupirdine to Treat Alzheimer Agitation Louie Pasculli

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

Latest News

Roger discusses how new therapies are transforming asthma treatment, enabling potential clinical remission.

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

News All Time

The Case for More Spirometry, Pulmonary Function Testing, with Meredith McCormack, MD Kevin Kunzmann

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Guidelines in Review: CHEST Advises Against Routine Blood Transfusions for Critically Ill Patients During Procedures Kevin Kunzmann

Evidence-based guidelines from emphasize personalized transfusion strategies for critically ill patients, urging clinicians to avoid routine platelet and fresh frozen plasma transfusions during common procedures.

What Ails Lung Cancer Screening, with Douglas Wood, MD Douglas Wood, MD

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

Clinical and Patient Definitions of Acute COPD Exacerbation Recovery Differ Greatly Kevin Kunzmann

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Dupilumab Lessens COPD Exacerbation Impact, with Nicola Hanania, MD, MS Nicola Hanania, MD, MS

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

Extended-Release Nalbuphine Improves Patient-Reported Refractory Chronic Cough Within 1 Week Imran Satia, MD, PhD

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Baseline Type 2 Biomarkers Can Predict Asthma Remission with Dupilumab, with Mario Castro, MD, MPH Kevin Kunzmann

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Dry Powder Treprostinil Tolerated Among Patients with PH-ILD, with Nicholas Kolaitis, MD Kevin Kunzmann

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Burden in Phase 3 SynAIRgy Kevin Kunzmann

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

From Slowing Decline to Restoring Function: Taladegib’s Promise in IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

Dupilumab Reduces Mucus Burden in Uncontrolled Asthma, with Njira Lugogo, MD Njira Lugogo, MD

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.

Dupilumab Bests Omalizumab in Airway Improvement for Patients with CRSwNP and Asthma Kevin Kunzmann

Data from the phase 4 head-to-head EVEREST trial further indicates dupilumab's benefit for type 2 inflammatory airway disease.

Defining the Future of Asthma Remission, With Linda Rogers, MD

Defining the Future of Asthma Remission, With Linda Rogers, MD

The Asthma and COPD Precision Medicine Era, with Nicola A. Hanania, MD, MS

The Asthma and COPD Precision Medicine Era, with Nicola A. Hanania, MD, MS

Personalized COPD Treatment: Lessons from Biologic Trials and Clinical Practice

Personalized COPD Treatment: Lessons from Biologic Trials and Clinical Practice

Early morning practices linked to less and lower-quality sleep in college athletes

A study using more than 27,000 sleep records of collegiate athletes provides the best evidence to date that early morning team practices take a toll on healthy sleep.

Recommended News For You

A study has developed molecular markers that predict meningioma recurrence.

Congress Ditched Fix to Medicare Doc Pay Cut in Skinny Budget Bill

Research exposes far-reaching toll of financial hardship on patients with cancer

Study Supports Lactated Ringer Solution for Fluid Resuscitation in SCD

EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer

healthy despite having advanced cancer.

According to the Lancet, having cancer and VTE at the same time increases mortality risk.

Recommended Articles For You

Exploring the Benefits of Endari: How This Natural Remedy Can Help You Live a Healthier Life 

Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools 

Ear Emergency: Understanding the Causes and Treatment for Auricular Hematoma 

A Mural of Thrombus: Unlocking the Power of Art to Combat Cardiovascular Disease 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study confirms link between breast density, higher breast cancer risk

2.

The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.

3.

By acquiring T3 Pharma, a leader in bacterial cancer treatment, Boehringer Ingelheim broadens its offering in immunooncology.

4.

Is global cancer care losing its human touch?

5.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

1.

Next-Gen Cancer Therapies: Radiopharmaceuticals, Immuno-Oncology, and Biologic Breakthroughs

2.

Unraveling the Genetic Mystery of Hereditary Spherocytosis

3.

AI Revolutionizes Immunotherapy: Unveiling Biomarkers with Machine Intelligence

4.

Exploring the Mysteries of MGUS: Uncovering the Causes and Treatments

5.

Seeing the Unseen: Examining Chancroid Through Images

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

2.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

3.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

4.

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

5.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot